GSDMD and fatty liver disease: As NF-κB serves as a critical upstream controller of MCP-1, TNF-α, and IL-1β expression, NF-κB signaling is inhibited in GSDMD−/− mice.466 Furthermore, GSDMD−/− mice show reduced expression of genes involved in lipogenesis and enhanced expression of genes associated with lipolysis, which attenuates hepatic steatosis.466 It is thus known that the mechanism of inhibiting GSDMD to control disease progression includes control of cytokines secretion, NF-κB activation, and lipogenesis.